Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» iptacopan
iptacopan
The 10 highest value R&D projects in biopharma
The 10 highest value R&D projects in biopharma
Fierce Biotech
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Flag link:
EHA 2023 – Astrazeneca keeps up its complement defense
EHA 2023 – Astrazeneca keeps up its complement defense
EP Vantage
EHA
AstraZeneca
Alexion
Soliris
Ultomiris
Novartis
iptacopan
PNH
Flag link:
Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Novartis’s iptacopan meets primary endpoint in Phase III PNH trial
Clinical Trials Arena
Novartis
clinical trials
PNH
iptacopan
Flag link:
Could This Be Novartis' Next Blockbuster Medicine?
Could This Be Novartis' Next Blockbuster Medicine?
Motley Fool
Novartis
iptacopan
PNH
Flag link:
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
ASH: Novartis says rare disease med 'stands on its own,' diving deeper into head-to-head win against AstraZeneca
Fierce Biotech
ASH 2022
Novartis
iptacopan
AstraZeneca
Flag link:
Novartis' iptacopan meets PhIII test in fight against rare blood disease
Novartis' iptacopan meets PhIII test in fight against rare blood disease
Endpoints
Novartis
clinical trials
paroxysmal nocturnal hemoglobinuria
iptacopan
Flag link:
Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3
Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3
Fierce Biotech
Novartis
iptacopan
clinical trials
Soliris
AstraZeneca
Ultomiris
Flag link:
Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial
Novartis’ oral drug iptacopan tops injectables in head-to-head PNH trial
Pharmaphorum
Novartis
iptacopan
clinical trials
PNH
Flag link:
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Novartis’ iptacopan hits the mark in rare kidney disease C3G
Pharmaforum
Novartis
iptacopan
C3G
kidney disease
Flag link:
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
EHA21: Novartis trumpets iptacopan as oral alternative to antibodies in PNH
Pharmaforum
Novartis
iptacopan
clinical trials
PNH
EHA
Flag link:
Novartis' Most Advanced Kidney Compound Shows Promise in C3G
Novartis' Most Advanced Kidney Compound Shows Promise in C3G
BioSpace
Novartis
ASN
C3G
clinical trials
iptacopan
Flag link: